Grifols Launches AlphaID At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD - Seite 2

AlphaID At Home is now available to order in the U.S. without cost through a secure HIPAA-compliant online portal. Once the at-home screening kit arrives, individuals simply collect their saliva sample and send it to a CLIA-certified lab for processing. After a few weeks, they can access their genetic results on the secure online portal. Individuals are encouraged to share the results with their doctor, as only a healthcare provider can make a diagnosis of alpha-1.

Cleared by the U.S. Food and Drug Administration (FDA) in November 2022 for direct-to-consumer use*, AlphaID At Home screens for the 14 most prevalently reported genetic mutations associated with alpha-1 – the most of any test of its kind – including the S, Z, F, I alleles, as well as rare and null alleles.

AlphaID At Home uses the same accurate genotyping test Grifols has manufactured and made available to physicians globally since 2018 to screen for alpha-1, a focus on diagnosis that has led to more than 1 million patients being screened with Grifols solutions over the last 20 years.

To order a free AlphaID At Home kit, please visit www.alphaidathome.com.

To learn more about genetic COPD, please visit www.geneticCOPDtest.com.

To learn more about alpha-1, please visit the Alpha-1 Foundation at www.alpha1.org.

*AlphaID At Home is cleared for U.S. residents 18 years or older. The receipt of this free testing service does not create any expectation or obligation to purchase or use any product or service offered by any manufacturer.

For media inquiries:

Caleb Fernandez-Schendt
[e-mail]
[phone]

Grifols Press Office
[e-mail]        
Tel. [phone]

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.